Anti-Interleukin-1 Therapy Does Not Affect the Response to SARS-CoV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases
Leonie Geck, Koray Tascilar, David Simon, Arnd Kleyer, Georg Schett, Jürgen Rech, Ferdinando Nicoletti · 2023
Read Anti-Interleukin-1 Therapy Does Not Affect the Response to SARS-CoV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases by Leonie Geck, Koray Tascilar, David Simon, Arnd Kleyer, Georg Schett, Jürgen Rech, Ferdinando Nicoletti (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10744315.txt.
Description
Leonie Geck, Jürgen Rech, and five co-authors asked if a class of drugs blunts vaccine response, in work from twenty twenty-three. The drugs block interleukin-1, a signal that drives swelling. Users have rare diseases where the body attacks itself, and they face high risk from COVID-19. The team checked shots and illness in one hundred patients and one hundred healthy peers.
After two shots, patients made just as much antibody as healthy peers, and the shots blocked the virus just as well. Illness after shots gave much the same levels. A third and fourth shot did not push levels higher. The team found no gap between the two main drugs in this class, and add-on drugs did no harm.
Catalog record
| CREATOR | Leonie Geck, Koray Tascilar, David Simon, Arnd Kleyer, Georg Schett, Jürgen Rech, Ferdinando Nicoletti |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |